A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)

被引：4
|
作者：
McLeod, E. J. [1 ]
Lloyd, A. [1 ]
Samyshkin, Y. [1 ]
Prunieras, F. [2 ]
Canney, P. [3 ]
机构：
[1] IMS Hlth, London, England
[2] ABRAXIS BIOSCI, Paris, France
[3] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71991-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [1] Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
    Alba, Emilio
    Ciruelos, Eva
    Lopez, Rafael
    Manuel Lopez-Vega, Jose
    Lluch, Ana
    Martin, Miguel
    Munoz, Montserrat
    Sanchez-Rovira, Pedro
    Angel Segui, Miguel
    Rubio Liria, Marta
    Perez-Alcantara, Ferran
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (03) : 381 - +
  • [2] A Spanish Cost-utility Analysis of Nab-paclitaxel Compared to Conventional Paclitaxel Monotherapy for Pretreated Metastatic Breast Cancer: Results From the COSTABRAX Study
    Alba, E.
    Ciruelos, E.
    Lopez, R.
    Lopez Vega, J. M.
    Lluch, A.
    Martin, M.
    Sanchez Rovira, P.
    Segui, M. A.
    Rubio Liria, M.
    Perez, F.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S117 - S117
  • [3] Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
    Dranitsaris, George
    Yu, Bo
    King, Jennifer
    Kaura, Satyin
    Zhang, Adams
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 249 - 256
  • [4] NAB-PACLITAXEL OR DOCETAXEL AS ALTERNATIVES TO SOLVENT-BASED PACLITAXEL IN METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS FROM A CHINESE HEALTH CARE PERSPECTIVE
    Dranitsaris, G.
    Yu, B.
    Qing, Z.
    King, J.
    Zhang, A.
    Kaura, S.
    VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
  • [5] A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC)
    Dranitsaris, George
    Yu, Bo
    King, Jennifer
    Zhang, Adams
    Kaura, Satyn
    Qing, Zhai
    CANCER RESEARCH, 2015, 75
  • [6] THE COST-EFFECTIVENESS OF NANOPARTICLE ALBUMIN-BOUND PACLITAXEL COMPARED TO SOLVENT-BASED PACLITAXEL IN WOMEN WITH METASTATIC BREAST CANCER
    Vandewalle, B.
    Almeida, J.
    Felix, J.
    Silva, M. J.
    Luz, R.
    VALUE IN HEALTH, 2011, 14 (07) : A451 - A451
  • [7] INDIRECT COMPARISON AND UK COST-EFFECTIVENESS ANALYSIS OF PACLITAXEL ALBUMIN VS DOCETAXEL FOR PRETREATED METASTATIC BREAST CANCER
    Prunieras, F.
    McLeod, E.
    Lloyd, A.
    Canney, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 107 - 108
  • [8] An Italian Cost-effectiveness Analysis of Paclitaxel Albumin (nab Paclitaxel) Vs Solvent-based Paclitaxel for Metastatic Breast Cancer Patients - the CONSTANZA Study
    Lazzaro, C.
    Bordonaro, R.
    Cognetti, F.
    Fabi, A.
    De Placido, S.
    Arpino, G.
    Marchetti, P.
    Botticelli, A.
    Pronzato, P.
    Martelli, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S93 - S93
  • [9] Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK)
    Dranitsaris, G.
    Lidgren, M.
    Lundkvist, J.
    Coleman, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 67 - 67
  • [10] Nab-paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries
    Dranitsaris, G.
    Lidgren, M.
    Lundkvist, J.
    Coleman, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345